Yes, a weight-loss drug can now treat obstructive sleep apnea, but only in a specific way. In December 2024, the FDA approved Zepbound (tirzepatide) for moderate-to-severe obstructive sleep apnea in adults with obesity, used alongside a reduced-calorie diet and more physical activity. It reduces apnea severity by helping you lose weight, and it works best as part of a plan, not as a replacement for a diagnosis or for CPAP.
You are not alone if the headlines left you hopeful and a little confused. The idea that a once-weekly injection might ease your sleep apnea is genuinely exciting, especially if CPAP has been a struggle. It is fair to want to know exactly what the drug does, who qualifies, and whether it could finally let you skip the mask.
At iSLEEP, we think you deserve the honest version, not the hype. So let us walk through what Zepbound actually is, what the FDA approval covers, what the trials showed, and why knowing your apnea-hypopnea index, before and after, matters more than ever.
The Numbers You Need to Know
-
On December 20, 2024, the FDA approved Zepbound as the first-ever drug treatment for moderate-to-severe obstructive sleep apnea in adults with obesity
-
In the approval trials, apnea events fell by roughly 27 to 30 per hour on tirzepatide versus about 5 to 6 per hour on placebo over 52 weeks
-
Participants lost approximately 18 to 20% of their body weight on the drug, and the FDA notes the apnea improvement is likely related to that weight reduction
What Is Zepbound (Tirzepatide)?
Zepbound is the brand name for tirzepatide, a once-weekly injectable medication that reduces appetite and food intake to drive weight loss.
It belongs to a class of drugs that act on the GLP-1 hormone pathway, the same family people know from diabetes and obesity treatment. Tirzepatide is also sold as Mounjaro for type 2 diabetes; Zepbound is the version approved for weight-related conditions. The key thing to understand is that it does not act directly on your airway. It works by helping you lose weight, and weight loss is what can lower your sleep apnea severity. Our guide on how weight gain is linked to sleep apnea explains that connection in more depth.
What the FDA Actually Approved
The December 2024 approval is specific, and the details matter for whether it applies to you.
The FDA approved Zepbound for the treatment of moderate-to-severe obstructive sleep apnea in adults with obesity, to be used in combination with a reduced-calorie diet and increased physical activity. It is the first medication ever approved for obstructive sleep apnea.
"Today's approval marks the first drug treatment option for certain patients with obstructive sleep apnea." - U.S. Food and Drug Administration, 2024
Read that wording carefully. The approval is for adults who have both moderate-to-severe OSA and obesity. It does not cover mild OSA, people without obesity, central sleep apnea, or children. And it is positioned as an addition to diet and exercise, not a standalone fix.
How Well Does It Work?
The results were meaningful, but they describe improvement, not a cure.
The approval rested on two 52-week trials involving 469 adults, one group already using positive airway pressure therapy and one not. Over the year, apnea events dropped by about 27 to 30 per hour on tirzepatide, compared with roughly 5 to 6 per hour on placebo. Participants also lost around 18 to 20% of their body weight. The FDA notes that the improvement in the apnea-hypopnea index is likely related to that weight reduction, which fits everything we know about how weight affects the airway.
It is worth knowing what your AHI means before you weigh those numbers, and our guide to what your AHI score really means breaks it down. A drop of 27 to 30 events per hour is substantial. At the same time, many people start well above that range, so a large improvement does not always mean their apnea is gone. The FDA reported that more participants on Zepbound reached remission or mild OSA with symptom resolution than those on placebo, which is encouraging but not the same as everyone being cured.
Does This Mean You Can Skip CPAP?
Not on your own, and not without testing. CPAP remains the standard of care, and the drug does not automatically replace it.
In one of the approval trials, participants kept using their PAP therapy throughout the 52 weeks. The drug was studied alongside standard care, not as a substitute for it. Many people who lose weight still have measurable apnea afterward, because anatomy and other factors do not fully reverse with weight loss alone. Our article on whether sleep apnea goes away on its own covers why improvement rarely equals complete resolution.
Stopping CPAP prematurely can leave you with dangerous, untreated apnea. Any change to your therapy should be guided by a follow-up sleep test and your physician, not by an assumption that the medication has done the whole job. For the broader landscape of options, see our overview of treating sleep apnea without surgery.
What About Ozempic and Other GLP-1 Drugs?
Only Zepbound (tirzepatide) is FDA-approved specifically for obstructive sleep apnea.
Drugs like Ozempic and Wegovy, which use semaglutide, are not approved for OSA, even though weight loss generally helps the condition. Because any apnea benefit comes from losing weight rather than a direct airway effect, the important question with any of these medications is the same: is your AHI actually changing? You cannot answer that by how you feel. It takes a measured baseline and a follow-up test.
Side Effects and Safety, Briefly
Like any prescription medication, Zepbound carries side effects and is meant to be managed by a physician.
The most common are gastrointestinal: nausea, diarrhea, vomiting, and constipation, especially as the dose increases. There are also more serious warnings the manufacturer and FDA outline, which your prescriber will review against your health history. This article cannot replace that conversation. The point here is simply that this is a real medication with real tradeoffs, prescribed and monitored by a clinician, not a casual add-on.
Why a Diagnosis Still Comes First
Whether or not a weight-loss drug is in your future, you need a diagnosis to know your starting point and to track any change.
A sleep test does three things a prescription cannot. It confirms you actually have obstructive sleep apnea rather than central apnea, which the drug does not treat. It establishes your baseline AHI, which is the number any improvement is measured against. And it gives you something to compare a future test to, so you can see whether weight loss has genuinely improved your apnea. With around 30 million U.S. adults affected and a large majority still undiagnosed, many people taking these drugs have never had their apnea measured at all. Our step-by-step guide to diagnosis explains the full pathway.
Our at-home sleep test makes getting that baseline easy. It is $189 flat, uses the WatchPAT One device with roughly 98% correlation to in-lab studies, and a board-certified physician reviews every result, usually within about 72 hours. If you start a weight-loss medication, a repeat test later shows whether your apnea has actually improved, instead of leaving you to guess.
FAQ
Is Zepbound FDA-approved for sleep apnea?
Yes, on December 20, 2024, the FDA approved Zepbound (tirzepatide) for moderate-to-severe obstructive sleep apnea in adults with obesity, used alongside a reduced-calorie diet and more physical activity. It is the first-ever drug approved for OSA. It is not approved for mild OSA, for people without obesity, or for central sleep apnea, and it is meant to complement, not replace, standard care.
Does Zepbound cure sleep apnea?
No, Zepbound reduces sleep apnea severity by promoting weight loss, which lowers your apnea-hypopnea index. In the approval trials, apnea events dropped by roughly 27 to 30 per hour, and more patients reached remission or mild OSA than on placebo. But many people still have measurable apnea afterward, so it manages OSA rather than curing it. A repeat sleep test confirms where you actually stand.
Can I stop using my CPAP if I take Zepbound?
Not on your own. CPAP remains the standard of care, and in the trials the PAP-using group continued therapy throughout the 52 weeks. Zepbound may lower your AHI over time, but only a follow-up sleep test and your physician can determine whether your therapy needs adjusting. Stopping CPAP prematurely can leave dangerous untreated apnea, so any change should be guided by repeat testing.
Do Ozempic or other GLP-1 drugs treat sleep apnea?
Only Zepbound (tirzepatide) is FDA-approved for obstructive sleep apnea. Ozempic, Wegovy, and similar semaglutide medications are not approved for OSA, even though weight loss generally helps. Because any improvement comes from losing weight, the key question is whether your AHI is actually changing, which requires a baseline and follow-up sleep test rather than assuming the drug fixed the problem.
Do I still need a sleep test if I am starting a weight-loss drug?
Yes, you need a diagnosis to confirm you have obstructive rather than central sleep apnea, learn your baseline AHI, and qualify for treatment. After losing weight, a retest shows whether your apnea actually improved. iSLEEP's at-home test is a flat $189 using the WatchPAT One device, with about 98% correlation to in-lab studies and physician-reviewed results in roughly 72 hours.
Hope, With a Clear Head
The Zepbound approval is genuinely good news. For the first time, there is a medication that can meaningfully reduce obstructive sleep apnea in adults with obesity. But the honest framing matters: it works through weight loss, it suits a specific group, and it complements rather than replaces both a diagnosis and standard therapy. The smartest move is to anchor any decision in real numbers.
That starts with knowing your AHI. Our at-home sleep test gives you a physician-reviewed baseline in about 72 hours, at $189 flat, so you can measure progress instead of guessing at it.
Finding your path to better sleep is within reach with iSleephst.com.
This article is for informational purposes only and is not a substitute for medical advice. Please speak with a sleep specialist or your healthcare provider before making decisions about diagnosis or treatment.
References
Related Articles
-
https://isleephst.com/blogs/news/what-your-ahi-score-really-means-and-when-to-worry
-
https://isleephst.com/blogs/news/can-weight-gain-be-linked-to-sleep-apnea
-
https://isleephst.com/blogs/news/how-doctors-diagnose-sleep-apnea-a-step-by-step-guide
Â
